Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity L Vanderbeke, P Van Mol, Y Van Herck, F De Smet, S Humblet-Baron, ... Nature communications 12 (1), 4117, 2021 | 204 | 2021 |
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology I Vanmeerbeek, J Sprooten, D De Ruysscher, S Tejpar, P Vandenberghe, ... Oncoimmunology 9 (1), 1703449, 2020 | 193 | 2020 |
Trial watch: dendritic cell vaccination for cancer immunotherapy J Sprooten, J Ceusters, A Coosemans, P Agostinis, S De Vleeschouwer, ... Oncoimmunology 8 (11), 1638212, 2019 | 133 | 2019 |
Necroptosis in immuno-oncology and cancer immunotherapy J Sprooten, P De Wijngaert, I Vanmeerbeek, S Martin, P Vangheluwe, ... Cells 9 (8), 1823, 2020 | 114 | 2020 |
Type I interferons and dendritic cells in cancer immunotherapy J Sprooten, P Agostinis, AD Garg International Review of Cell and Molecular Biology 348, 217-262, 2019 | 99 | 2019 |
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer RS Laureano, J Sprooten, I Vanmeerbeerk, DM Borras, J Govaerts, ... Oncoimmunology 11 (1), 2096363, 2022 | 67 | 2022 |
Type I interferons and endoplasmic reticulum stress in health and disease J Sprooten, AD Garg International review of cell and molecular biology 350, 63-118, 2020 | 65 | 2020 |
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer J Sprooten, A Vankerckhoven, I Vanmeerbeek, DM Borras, Y Berckmans, ... Journal for Immunotherapy of Cancer 9 (11), 2021 | 28 | 2021 |
Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer S Naulaerts, A Datsi, DM Borras, A Antoranz Martinez, J Messiaen, ... Science Translational Medicine 15 (691), eadd1016, 2023 | 22 | 2023 |
Identification of potential prognostic and predictive immunological biomarkers in patients with stage I and stage III non-small cell lung cancer (NSCLC): a prospective … RDW Vaes, K Reynders, J Sprooten, KT Nevola, KMA Rouschop, ... Cancers 13 (24), 6259, 2021 | 21 | 2021 |
Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy I Vanmeerbeek, DM Borras, J Sprooten, O Bechter, S Tejpar, AD Garg Genes & Immunity 22 (2), 108-119, 2021 | 20 | 2021 |
Trial watch: chemotherapy-induced immunogenic cell death in oncology J Sprooten, RS Laureano, I Vanmeerbeek, J Govaerts, S Naulaerts, ... Oncoimmunology 12 (1), 2219591, 2023 | 18 | 2023 |
The interface of tumour-associated macrophages with dying cancer cells in immuno-oncology I Vanmeerbeek, J Govaerts, RS Laureano, J Sprooten, S Naulaerts, ... Cells 11 (23), 3890, 2022 | 11 | 2022 |
Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer DM Borràs, S Verbandt, M Ausserhofer, G Sturm, J Lim, GA Verge, ... Cell Discovery 9 (1), 114, 2023 | 9 | 2023 |
Immunogenomic, single-cell and spatial dissection of CD8+T cell exhaustion reveals critical determinants of cancer immunotherapy S Naulaerts, DM Borras, AA Martinez, J Messiaen, Y Van Herck, L Gelens, ... BioRxiv, 2021.11. 22.468617, 2021 | 7 | 2021 |
A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology J Sprooten, A Coosemans, AD Garg Oncoimmunology 11 (1), 2024692, 2022 | 5 | 2022 |
A lymph node-to-tumour PDL1+macrophage circuit antagonizes dendritic cell immunotherapy J Sprooten, I Vanmeerbeek, A Datsi, J Govaerts, DM Borràs, S Naulaerts, ... bioRxiv, 2023.03. 14.532534, 2023 | 2 | 2023 |
Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells J Sprooten, I Vanmeerbeek, A Datsi, J Govaerts, S Naulaerts, ... Cell Reports Medicine 5 (1), 2024 | 1 | 2024 |
The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapy RS Laureano, I Vanmeerbeek, J Sprooten, J Govaerts, S Naulaerts, ... Immunological Reviews 321 (1), 71-93, 2024 | 1 | 2024 |
77P Identification of prognostic and predictive immunological biomarkers in stage I and III non-small cell lung cancer (NSCLC) patients: A prospective exploratory study R Vaes, K Reynders, J Sprooten, K Nevola, A Garg, M Lambrecht, ... Annals of Oncology 32, S389, 2021 | 1 | 2021 |